Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress
Why Vision Marine Technologies Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Alliance Global Partners Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6
Vivos Therapeutics Analyst Ratings
A. G. P. Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $6
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript Summary
Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
Vivos Therapeutics Eyes Positive Cash Flow as It Continues Cost-reduction Success in Q3 | NASDAQ:VVOS
Vivos Therapeutics | 10-Q: Q3 2024 Earnings Report
Vivos Therapeutics 3Q Rev $3.86M >VVOS
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q3 Revenue $3.9M
Express News | Vivos Therapeutics Q3 Net Income USD -2.616 Million
Press Release: Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
Market Might Still Lack Some Conviction On Vivos Therapeutics, Inc. (NASDAQ:VVOS) Even After 27% Share Price Boost
Earnings Scheduled For November 14, 2024
Earnings Preview: VVOS to Report Financial Results Post-market on November 14
Vivos Therapeutics Gains AMA Approval for New Medical Codes, Expanding Access to Sleep Apnea Treatment
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Why Vivos Therapeutics (VVOS) Stock Is Down 25% on Thursday